Get the Stockscreener App
220.43
0.80%
1.76
After Hours:
219.41
-1.02
-0.46%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $220.43, with a volume of 7.79M.
It is up +0.80% in the last 24 hours and down -4.51% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$218.67
Open:
$218
24h Volume:
7.79M
Relative Volume:
1.29
Market Cap:
$389.58B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
166.32
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
+1.06%
1M Performance:
-4.51%
6M Performance:
+15.28%
1Y Performance:
+25.77%
1-Day Range:
$218.00
$224.14
1-Week Range:
$215.88
$226.86
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
220.43 | 386.47B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,024.14 | 916.32B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.29 | 548.64B | 94.19B | 26.80B | 20.46B | 11.05 |
|
NVS
Novartis Ag Adr
|
148.91 | 283.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
108.34 | 265.33B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Spinal Cord Injury Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Kringle Pharma, Neuroplast, AbbVie, and Mitsubishi Tanabe Pharma America - Barchart.com
AbbVie Launches Love in Mind to Spotlight the Emotional Impact of Migraine on Romantic Relationships - Investing News Network
3 in 4 with migraine say attacks hurt their romantic lives - Stock Titan
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
AbbVie (ABBV) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Why AbbVie Stock Trounced the Market in 2025 - Finviz
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call - Finimize
Taking The First Steps Towards Digitalizing Biopharma Development - Bioprocess Online
UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs - Benzinga
AbbVie's Irish operations in firing line as Trump targets Botox prices - Irish Examiner
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq
AbbVie Partners with Trump Administration to Enhance Access and Affordability - Intellectia AI
AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades' - Benzinga
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle - Benzinga
CMS Names Pfizer, Eli Lilly, and AbbVie Drugs for Third Medicare Price Talks - TipRanks
Does AbbVie's Bispecific Trial Win and R&D Pledge Change The Bull Case For AbbVie (ABBV)? - Yahoo Finance
US names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - wkzo.com
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks - Yahoo! Finance Canada
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks - Investing.com Canada
AbbVie stock rises as insurers crater and the Fed week kicks off - TechStock²
Citigroup Issues Pessimistic Forecast for AbbVie (NYSE:ABBV) Stock Price - MarketBeat
Citigroup Adjusts Price Target for AbbVie (ABBV) to $230, Mainta - GuruFocus
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Is the Options Market Predicting a Spike in AbbVie Stock? - TradingView
J. Safra Sarasin Holding AG Purchases 62,723 Shares of AbbVie Inc. $ABBV - MarketBeat
Berenberg Grows More Confident in AbbVie (ABBV) on Skyrizi and Rinvoq Momentum - Finviz
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings - TechStock²
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings - TechStock²
How Recent Price Target Rethinks Are Rewriting The Story For AbbVie (ABBV) - Yahoo Finance
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vanguard Personalized Indexing Management LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Parthenon LLC - MarketBeat
AbbVie Inc. $ABBV Stake Cut by Lbp Am Sa - MarketBeat
AbbVie Inc. $ABBV Position Cut by Mutual of America Capital Management LLC - MarketBeat
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
AEGON ASSET MANAGEMENT UK Plc Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV): Investor Outlook and Potential 11.84% Upside with Strong Analyst Support - DirectorsTalk Interviews
Commerzbank Aktiengesellschaft FI Sells 39,586 Shares of AbbVie Inc. $ABBV - MarketBeat
Cullen Frost Bankers Inc. Has $88.49 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
West to Sell SmartDose 3.5mL System to AbbVie in $112.5M Deal - mychesco.com
AbbVie is a top dividend stock as drug pipelines drive payout hikes - thestreet.com
Mn Services Vermogensbeheer B.V. Has $155.25 Million Position in AbbVie Inc. $ABBV - MarketBeat
Resona Asset Management Co. Ltd. Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 18,081 Shares of AbbVie Inc. $ABBV - MarketBeat
UniSuper Management Pty Ltd Has $58.21 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Jennison Associates LLC - MarketBeat
Delta Financial Advisors LLC Purchases 4,830 Shares of AbbVie Inc. $ABBV - MarketBeat
TrueMark Investments LLC Lowers Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie stock rises as India rejects Venetoclax patent bid; ABBV traders eye Feb. 4 earnings - TechStock²
AbbVie Inc. $ABBV Shares Sold by Lockheed Martin Investment Management Co. - MarketBeat
Indian Patent Office rejects AbbVie patent bid for cancer drug Venetoclax; generics may enter market - domain-b.com
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
1.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):